0001437749-23-018918.txt : 20230731 0001437749-23-018918.hdr.sgml : 20230731 20230629170136 ACCESSION NUMBER: 0001437749-23-018918 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 CORRESP 1 filename1.htm pyxs20230623_corresp.htm

 

June 29, 2023

 

Via EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

 

 

Attention:         Dillon Hagius

 

 

Re:

Acceleration Request for Pyxis Oncology, Inc.

   

Registration Statement on Form S-4 (File No. 333-272510)

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pyxis Oncology, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-4, Registration Number 333-272510 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 3:00 P.M., Eastern Time or as soon thereafter as practicable, on June 30, 2023, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.

 

We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin LLP at (212) 839-5651.

 

 

 

[Signature Page Immediately Follows]

 

 

 

 

 

 

Very truly yours,

 

  /s/ Pamela Connealy
 

 

Pamela Connealy
Chief Financial Officer

 

cc:

Lara Sullivan, Pyxis Oncology, Inc.

Asher Rubin, Sidley Austin LLP

Frank Rahmani, Sidley Austin LLP

Istvan A. Hajdu, Sidley Austin LLP